Nintedanib for the treatment of non-small-cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 5, 2014, Pages 729-739

  Rashdan, Sawsan ^a   Hanna, Nasser ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Angiogenesis; Fibroblast growth factor; Nintedanib; NSCLC; Platelet derived growth factor; Tyrosine kinase inhibitors; VEGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FIBROBLAST GROWTH FACTOR RECEPTOR; NINTEDANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MEMBRANE PERMEABILITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESISTANCE; DRUG SAFETY; ENZYME INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84896258821     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.897695     Document Type: Article

References (52)

1. American Cancer Society. What is nonsmall cell lung cancer? American. Cancer Society. Detailed guide: lung cancer - non-small cell. Available from: http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/ non-smallcell- lung-cancer-what-is-non-small-celllung-cancer [Accessed 15 November 2013]
2. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42
3. Carney DN. Lung cancer - time to move on from chemotherapy. N Engl J Med 2002;346:126-8
4. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-6
5. Macchiarini P, Fontanini G, Dulmet E, et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994;57:1534-9
6. Giatromanolaki A, Koukourakis M, OByrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996;179:80-8
7. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002;87:694-701
8. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
10. Yuan A, Yu C-J, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19:432-41
11. Delmotte P, Martin B, Paesmans M, et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis [in French]. Rev Mal Respir 2002;19:577-84
12. Presta M, DellEra P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
13. Donnem T, Al-Shibli K, Al-Saad S, et al. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGFB predicts poor survival. J Thorac Oncol 2009;4:578-85
14. Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005;65:5561-70
15. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5
16. Ton NC, Jayson GC. Resistance to anti VEGF agents. Curr Pharm Des. 2004;10:51-64
17. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21
18. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
19. Oikawa T, Onozawa C, Sakaguchi M, et al. Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol Pharm Bull 1994;17:1686-8
20. Risau W, Drexler H, Mironov V, et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992;7:261-6
21. Kano MR, Morishita Y, Iwata C, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118:3759-68
22. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117:2766-77
23. Cao H, Zhang H, Zheng X, Gao D. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family. J Mol Graph Model 2007;26:236-45
24. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
25. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52:4466-80
26. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89
27. Stopfer P, Roth W, Mross KB, et al. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Eur J Cancer Suppl 2006;4:26
28. Hilberg F, Brandstetter I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy. Eur J Cancer 2007;2:S380
29. Daga H, Takeda K, Okada H, et al. Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in japanese patients with advanced or recurrent nonsmall cell lung cancer (NSCLC): a phase I study. J Clin Oncol 31 2013(Suppl):abstract 8056
30. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-19
31. Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16:2881-9
32. Doebele RC, Conkling P, Traynor AM, et al. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012;23:2094-102
33. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
34. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22:1374-81
35. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6
36. Blumenschein G, Gatzemeier U, Fosella F, et al. Phase II trial of singleagent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006;24:abstract 7002
37. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-smallcell lung cancer. J Clin Oncol 2011;29:1059-66
38. Gauler TC, Besse B, Mauguen A, et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as secondline monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 2012;23:678-87
39. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet 2013;2:143-55
40. Hanna N, Kaiser R, Sullivan R, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 31 2013(Suppl):abstract 8034
41. Sandler A, Gray R, Perry M. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
42. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomized, phase 3 trial. Lancet Oncol 2010;11:619-26
43. De Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29:1067-74
44. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase iii trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol 2010;28:3617-22
45. Polcher M, Rudlowski C, Friedrichs N. In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer. BMC Cancer 2010;10:137
46. Ng S, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro influence of formulation vehicles and binding proteins. Cancer Res 2004;64:821-4
47. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335
48. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
49. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735
50. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239
51. Shaw A, Kim D, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
52. OBrien S, Guilhot F, Larson R, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004